Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 12 Publications

5 Customer Reviews

  • Tumors were resected from mice 10 days after orthotopic inoculation of 4T1-Luc2 cells, and hydrogels loaded with the following payloads were evaluated: anti–PD-1, anti-CTLA-4, IL-15sa, lenalidomide, celecoxib, STING-RR, or R848. Mice that did not receive a hydrogel were examined as a negative control. (A) IVIS imaging of 4T1-Luc2 cells is shown for all groups described and illustrates tumor burden.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Celecoxib purchased from Selleck.

    Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

  • Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

    Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable (negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001

    J Transl Med, 2017, 15(1):46. Celecoxib purchased from Selleck.

  • Oncol Lett, 2018, 16(1):317-325. Celecoxib purchased from Selleck.

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MUTGeY5kfGmxbjDBd5NigQ>? MmnQNE4yNTNyIN88US=> Mny2OFghcA>? NF;BSGFqdmS3Y3XzJGlESU1vMTDlfJBz\XO|aX;uJI9vKGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdA>? M4DiSVI3PTF|MUey
H460 NHTNT2lHfW6ldHnvckBCe3OjeR?= MUKwMlEuOzBizszN MYq0PEBp NHHJV|JqdmS3Y3XzJGlESU1vMTDlfJBz\XO|aX;uJI9vKGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdA>? MVuyOlUyOzF5Mh?=
HKESC-2 NH3MV5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUWyNOKh|ryP NH3VdIw1QMLiaNMg NW\KeYFke2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi MY[yOlQ4PDZ7Mx?=
CaES-17 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe1T2kzOMLizszN NWTGOnM1PDkEoHlCpC=> NWTMbnVwe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi M1G0eVI3PDd2Nkmz
HKESC-2 MUPBdI9xfG:|aYOgRZN{[Xl? MXOyNOKh|ryP NVXE[YY{PDkEoHlCpC=> M{T6dpJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> NILXTmMzPjR5NE[5Ny=>
CaES-17 MVLBdI9xfG:|aYOgRZN{[Xl? M3jCbVIxyqEQvF2= MWW0POKhcMLi NHrHXHFz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ MkDINlY1PzR4OUO=
A549 NHfkTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DsNlUuOTZyIN88US=> M2Xhb|Q5yqCqwrC= MULEUXNQ NGP4OXhKSzVyPUG2N{41KM7:TR?= M3jH[FI3PDZ2NkSz
HCC827 NGi5WYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrWR3FmPS1zNkCg{txO NISxOI01QMLiaNMg NW\qW2JCTE2VTx?= NH3jO4JKSzVyPU[5MlIh|ryP Mn;BNlY1PjR4NEO=
A549 NEC3[XFCeG:ydH;zbZMhSXO|YYm= MnnUPFAhyrWP MYm0POKhcMLi MkOxSG1UVw>? MkDCbY5lfWOnczDhdI9xfG:|aYO= NHz0[FIzPjR4NE[0Ny=>
HCC827 NUfiR494SXCxcITvd4l{KEG|c3H5 MX[4NEDDvU1? MVu0POKhcMLi MVXEUXNQ NWPZfIZ3cW6mdXPld{BieG:ydH;zbZM> M3;KdlI3PDZ2NkSz
SGC-7901/DDP MYfGeY5kfGmxbjDBd5NigQ>? M4DvfVExyqEEtV2= M{LoUFI1KGh? NHXST3FqdmirYnn0d{BkgWOub3;4fYdmdmG|ZT2yJIFv\CCSLXfsfYNweHKxdHXpckBmgHC{ZYPzbY9v M3\WelI3PDB5NkWz
SGC-7901  NULW[nN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXt[|Y4OjUEoHlCpC=> M1;h[WlEPTB;MUG1MlA5KM7:TR?= NUm1S3FTOjZ2MEe2OVM>
SGC-7901/DDP M1SxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;5NlTDqGkEoB?= M2KzXWlEPTB;M{WuOFUh|ryP MnHwNlY1ODd4NUO=
SGC-7901/DDP NUHwTodISXCxcITvd4l{KEG|c3H5 MlrpNVDDqML3TR?= Mo\MNlQhcA>? NF\CUJpqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIIfpeIgh[2m|cHzheIlv M3j5e|I3PDB5NkWz
SGC-7901/DDP NU\PUpNQTnWwY4Tpc44hSXO|YYm= M{\xTFExyqEEtV2= MX:yOEBp MXvpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDQMYdtgWOxcILveIVqdiC2aILveYdpKGKub3PrbY5oKEWSMjygZY5lKGmwYXP0bZZifGmwZzDQT2Eh[W6mIFPSSWLDqA>? NX70e2syOjZ2MEe2OVM>
SGC-7901/DDP NVOyWY5TTnWwY4Tpc44hSXO|YYm= NVfydYczOTEEoNM1US=> NVrmepNmOjRiaB?= Mnj3Z4F2e2W|IHGgcYFzc2WmIHTlZ5Jm[XOnIHnuJJRp\SCuZY\lcEBw\iCEY3ytNkBxem:2ZXnu MVyyOlQxPzZ3Mx?=
H357 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYq3MlUwOTBizszN M4nuZ|Q5KGh? MVnEUXNQ M1fwVIlvcGmkaYTzJINmdGxiZ4Lve5RpyqClb33ibY5m\CC5aYToJHNi[nW2b3PsZZg> MoS0NlYxODl6N{S=
TAF MoHFSpVv[3Srb36gRZN{[Xl? MUCxNOKhyrWP NV7tTIRRPyCm MXHh[oZm[3S|IGTBSpMh[WSqZYPpeoUheHKxcHXyeIlmew>? NES5[GwzPTl6N{GyOy=>
TAF Mnv1SpVv[3Srb36gRZN{[Xl? M3ftR|ExyqEEtV2= MkDMN|AuOTJyIH3pci=> NH:xdYxxd2:{bImgZYZn\WO2czDkRYt1KHCqb4PwbI9zgWyjdHnvckBkd26|ZYH1[Y51KHSxIFXHSkB{cWewYXzpcoc> NEjxVFIzPTl6N{GyOy=>
TAF MkfPSpVv[3Srb36gRZN{[Xl? MXixNOKhyrWP NEDvUZI1QCCq MkPBbY5kemWjc3XzJGVITlJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w M4jnXVI2QTh5MUK3
PANC-1 MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGwPGIxOjBxNkCvNVAxKM7:TR?= M{fFSlI1NzR6L{eyJIg> Mnr2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? Mo\FNlU6PzNyNkK=
PANC-1 NF;IWmtHfW6ldHnvckBCe3OjeR?= M3zGPVIxNzZyL{GwNEDPxE1? M{XTblI1KGh? M1;RZoF1fGWwdXH0d{Bk\WyuIHnueoF{cW:wIHHu[EBucWe{YYTpc44hcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MnTkNlU6PzNyNkK=
HeLa  MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCyNOKh|ryPwrC= Ml[wNlTDqGh? M17TUIVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w NIDRZpgzPTd5MESyNy=>
SACC-83 M4Tjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKyNOKh|ryPwrC= MXGyOOKhcA>? NGTMbpFmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?= MWeyOVc4ODR{Mx?=
HeLa  MU\BdI9xfG:|aYOgRZN{[Xl? MXGyNOKh|ryPwrC= NYHUTpNbOjUEoHi= M4n1e4VvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> M3P0cVI2PzdyNEKz
SACC-83 NVzUZ4d7SXCxcITvd4l{KEG|c3H5 M{niZlIxyqEQvF5CpC=> MUCyOOKhcA>? MYXlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygZZBweHSxc3nz MmDCNlU4PzB2MkO=
HeLa  M13WTWZ2dmO2aX;uJGF{e2G7 MojPNlAwPDBxOECg{txO M4PMR|I1yqCq M3X5PJVxemWpdXzheJMhWFSHTjDwZZJ1cWGubImgZpkhcW6qaXLpeIlv\yCVcEGsJIFv\CCjY4TpeoF1\XNiUGTFUkBidmRiaX7hZ5RqfmG2ZYOgRWtV M{fPWFI2PzdyNEKz
SACC-83 MV7GeY5kfGmxbjDBd5NigQ>? NE[zTnozOC92MD:4NEDPxE1? NEnFTXAzPMLiaB?= MXz1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> NVnvVG5POjV5N{C0NlM>
HLCZ01 M13IWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L2U|DjiJN4MNMgxtVO NUPoXJlTPDhiaB?= M4nj[WROW09? M1Xtd4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MVyyOVczPDh7OR?=
HLCZ01 MkPXSpVv[3Srb36gRZN{[Xl? M1zRdVQxyqEQvF2= NF;jV4czPCCq NWfiblZyTE2VTx?= M4fYdYlv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE> NV7Pe3NQOjV5MkS4PVk>
HLCZ01 M1jxWGFxd3C2b4Ppd{BCe3OjeR?= MYq0NOKh|ryP NVHKUnB6OjRiaB?= Ml7aSG1UVw>? M2[wcoVvcGGwY3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>? MWeyOVczPDh7OR?=
HLCZ01 MWPGeY5kfGmxbjDBd5NigQ>? NWXXPXh1PDEEoN88US=> NYTxOG9JOjRiaB?= M1PLO2ROW09? M2PmfYlv[3KnYYPld{BVWkGLTDDlfJBz\XO|aX;uJINwdWKrbnXkJJdqfGhiSX70[ZJn\XKxbj5OtS=> NHrONYczPTd{NEi5PS=>
MGC803 NF[0OIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nyfVAuPjBizszN NWC3VWNZPzJiaB?= MVnJR|UxRTR5LkK15qCKyrIkgJm2MlQ{KM7:TR?= NIHpTYYzPTdyMUO3PC=>
SGC7901 NHm5ZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXWwMVYxKM7:TR?= Mk\JO|IhcA>? M2\VRmlEPTB;NEOuOVPjiIoEsfMAjVUvOTJizszN MUmyOVcxOTN5OB?=
MGC803 MlzISpVv[3Srb36gRZN{[Xl? MkfGOFDDqM7:TR?= MlP3PE8yPi9{NDDo NXG0OlZqfXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v M2fERlI2PzBzM{e4
SGC7901 MmPhSpVv[3Srb36gRZN{[Xl? MVu0NOKh|ryP NUnubWtoQC9zNj:yOEBp M3X1WpVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> M4HsflI2PzBzM{e4
MCF-7  M4nFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;KNU8yOCEQvF2= NFLJcWg4OiCq MnizSG1UVw>? NE\DNFdmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?= MojLNlU3Pjd3MUC=
MDA-MB-231  MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1f5UVEwOTBizszN NGDaVFI4OiCq MoXCSG1UVw>? M2HBV4VvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w MVSyOVY3PzVzMB?=
MDA-MB-231 MkXlSpVv[3Srb36gRZN{[Xl? NEjucIMxNTRyINM1US=> NIDjcnk1NTJ2IHi= M2no[4lv[3KnYYPld{BEV1hvMjDwdo91\WmwIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M3j3VFI2PTh5M{K5
MCF-7 NHnMOYVHfW6ldHnvckBCe3OjeR?= MYqwMVQxKML3TR?= M1jBS|QuOjRiaB?= NW\4W3JP\W6qYX7j[ZMhfGinIHXm[oVkfHNib3[gWHBCKG:wIFHCR2czKGW6cILld5Nqd28EoB?= NYnMW5lSOjV3OEezNlk>
MCF7-MX  MUnGeY5kfGmxbjDBd5NigQ>? NX;ZNWlkOC12MDFCuW0> Mm\WOE0zPCCq NHu5c3VmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS|Ih\XiycnXzd4lwdsLi MnnNNlU2QDd|Mkm=
MDA-MB-231 NVHHOodMTnWwY4Tpc44hSXO|YYm= Ml74NE01OCEEtV2= M13TWlQuOjRiaB?= MYTzeIlufWyjdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGFDS0d{IIXwJJRwKDRwMkegeIlu\XNidH:gZ49vfHKxbDDs[ZZmdCCkeTCxNkBpyqB? M{S3U|I2PTh5M{K5
A2780 M2\Fd2Z2dmO2aX;uJGF{e2G7 NHq2bZg2NzFyL{G1JO69VQ>? NFvLfGQ1QCCq M3zH[YRm[3KnYYPld{BEd3hvMjDlfJBz\XO|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NHPRSXgzPTR{NEi5PC=>
SKOV3  NHm3dlJHfW6ldHnvckBCe3OjeR?= Mm[3OU8yOC9zNTFOwG0> MonwOFghcA>? MUDk[YNz\WG|ZYOgR495NTJiZYjwdoV{e2mxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUKyOVQzPDh7OB?=
A2780 MmjWSpVv[3Srb36gRZN{[Xl? M33mN|UwOTBxMUWg{txO NV;1V5BRPDhiaB?= NX7aSohH\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= NWe1NnR3OjV2MkS4PVg>
SKOV3  Mn\4SpVv[3Srb36gRZN{[Xl? MUK1M|ExNzF3IN88US=> MUe0PEBp NHj6b5lmdGW4YYTld{B1cGViZYjwdoV{e2mxbjDv[kBGNWOjZHjldolvKGGwZDDr[ZJifGmw NHfZUXQzPTR{NEi5PC=>
A2780 MkKxSpVv[3Srb36gRZN{[Xl? MojGOU8yOC9zNTFOwG0> MnTlOFghcA>? M{P3OoRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?= MYqyOVQzPDh7OB?=
SKOV3  Mkf3SpVv[3Srb36gRZN{[Xl? NVm4PJd6PS9zMD:xOUDPxE1? NF3NRlM1QCCq MXvk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5? Ml76NlU1OjR6OUi=
A2780 NGPQN5hHfW6ldHnvckBCe3OjeR?= MWK1M|ExNzF3IN88US=> M2fJSFEhcA>? MXLpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NV;OfZJwOjV2MkS4PVg>
SKOV3  M3y3e2Z2dmO2aX;uJGF{e2G7 NVXGO3AyPS9zMD:xOUDPxE1? MnuxNUBp NF64W2FqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVXRTI1nOjV2MkS4PVg>
HCT-15 NHOzd5lHfW6ldHnvckBCe3OjeR?= MWqxNE02OCEQvF2= MYS2MVM3KGh? MVPpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ NXvQSJVEOjV{MUiwNlg>
HT-29  NYThN4VwTnWwY4Tpc44hSXO|YYm= NXe2dG5HOTBvNUCg{txO NHrjdWY3NTN4IHi= MnvvbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= M1TnZlI2OjF6MEK4
HSC3  MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVPmdGNwOOLCk{SwJO69VQ>? NFnwbXI1QCCq MnjmTWM2OD1{NT61xtEyNjd6MDFOwG0> MkH6NlUyQTh5OEm=
HSC3  MlyzRZBweHSxc3nzJGF{e2G7 MYKyOUDPxE1? MX:0PEBp NGja[ZNqdmS3Y3XzJIFxd3C2b4Ppdy=> NF7MWJozPTF7OEe4PS=>
HSC3  M4jqNGZ2dmO2aX;uJGF{e2G7 NFzKcI4zPSEQvF2= MoHROFghcA>? M2nwPIV5cGmkaYTzJJNq\26rZnnjZY51dHlicnXkeYNm\CCvaXfyZZRqd25iY3;tZolv\WRid3n0bEBETVR? NWHheoF[OjVzOUi3PFk>
HSC3  MYXGeY5kfGmxbjDBd5NigQ>? NFfJeXYzPSEQvF2= MXq0PEBp NVO0XlV1cW6qaXLpeJMhUFOFMzDj[YxtKGmwdnHzbY9vKGOxbXLpcoVlKHerdHigR2VV NXfGd4k5OjVzOUi3PFk>
HSC3  NV\FdWdZTnWwY4Tpc44hSXO|YYm= M1:yeVI2KM7:TR?= MWC3NkBp MlLz[IVkemWjc3XzJG1OWC1{IHHu[EBOVVBvOTDwdo91\Wmwc9Mg NG\wZXYzPTF7OEe4PS=>
201T  NWXLd|ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\ubFczKGh? MkTOSG1UVw>? MVXJR|UxRTR6Lk[gxtVO Mnn5NlUxPTd7NEG=
273T NVfuO4NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f4blczKGh? NH7hRZRFVVOR NEHGUJhKSzVyPUiwMlUhyrWP MlfDNlUxPTd7NEG=
Hep-2 NWO1dY91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXvN|AwPTBxMUCwJO69VQ>? M1jKTVEzNzJ2L{O2M|Q5KGh? MlPSSG1UVw>? M1zKNYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NF\PW2kzPDl7OEW2OC=>
Hep-2 M3\BR2Fxd3C2b4Ppd{BCe3OjeR?= MnHiOVAh|ryP MXywMVQ5KGh? NUPq[pAyTE2VTx?= NVnvZ3ZRcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MnntNlQ6QTh3NkS=
Hep-2 MULGeY5kfGmxbjDBd5NigQ>? NVXWbVBOPTBizszN NYjqbW9tOC12ODDo MVTEUXNQ NVrWOJJjemWmdXPld{B1cGVidHXsc41memG|ZTDhZ5Rqfmm2eTDndoFlfWGubIm= M3rUcFI1QTl6NU[0
Hep-2 NEHvSXdHfW6ldHnvckBCe3OjeR?= M4TZblUxKM7:TR?= MWCwMVQ5KGh? MXzEUXNQ NGr1XZVl\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDoWGVTXA>? M3OyVlI1QTl6NU[0
SGC-7901 Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOxNE82OC9zMECg{txO MUSyOE81QC95MjDo NHfjR2JFVVOR NHvOeoJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= Ml\GNlQ6QTJ7NUi=
MKN-45 NHK4ZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDUU5BnOTBxNUCvNVAxKM7:TR?= NGTHXW4zPC92OD:3NkBp NXzadYZtTE2VTx?= MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NVvncWtROjR7OUK5OVg>
SGC-7901 NUT1O2Z6TnWwY4Tpc44hSXO|YYm= MUmxNE82OC9zMECg{txO NF\2bXc1QCCq M1jyWWROW09? MUnkc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M{\EN|I1QTl{OUW4
MKN-45 NFS4W|lHfW6ldHnvckBCe3OjeR?= M2rZRlExNzVyL{GwNEDPxE1? NE\NfpU1QCCq MXHEUXNQ MWTkc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NWmwdG5OOjR7OUK5OVg>
C666-1 NEOzZWlEgXSxdH;4bYNqfHliQYPzZZk> NUnIb25pOjBvOECg{txO MlO1NlQhcA>? MVLk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg NH3YO24zPDh3NEizPC=>
CNE-1 M1rsV2N6fG:2b4jpZ4l1gSCDc4PhfS=> M2LBUFIxNThyIN88US=> NHTjdW4zPCCq M3rwOYRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> NYDTXlNKOjR6NUS4N|g>
CNE-2 MWDDfZRwfG:6aXPpeJkhSXO|YYm= NEP4[W0zOC16MDFOwG0> MV6yOEBp MVLk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg NVu0S2VSOjR6NUS4N|g>
C666-1 NVnWW4NQS3m2b4TvfIlkcXS7IFHzd4F6 MXi2NEDPxE1? NUmwbmZzPyCm NVfsWnE5\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> NXLuN5U5OjR6NUS4N|g>
CNE-1 MmHoR5l1d3SxeHnjbZR6KEG|c3H5 M1XHUFYxKM7:TR?= MX63JIQ> NVrVfmNF\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> MlvDNlQ5PTR6M{i=
SNU-1041 M3nz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXVXJpnOC12MDFOwG0> MU[0PEBp NXyzTVV4cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NIq2XI0zPDZ7MkewNy=>
SNU-1041 MmDySpVv[3Srb36gRZN{[Xl? NFLyN5ozOC9|MDFOwG0> NU[wT4FtPCCq Mnv2bY5lfWOnczDlfJBz\XO|aX;uJI9nyqCFSF;QMEBIWlB5ONMgZY5lyqC[QmCxxsBifCC2aHWgVm5CKGyndnXsxsA> NUSxWYFJOjR4OUK3NFM>
SNU-1041 M2\KbGZ2dmO2aX;uJGF{e2G7 M3TyVlAuPDBizszN MUi0JIg> M4TzXZVxNXKnZ4XsZZRmeyCFSF;QxsBi\nSncjD0doVifG2nboSge4l1cCCqaXfoJINwdmOnboTyZZRqd26| MmDmNlQ3QTJ5MEO=
SGC-7901 NVnqOpZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjIT482OC1zMkWg{txO MlvENlQwPDhxN{KgbC=> MWLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MYiyOFY4PjN7NB?=
SGC-7901 M4PTOmFxd3C2b4Ppd{BCe3OjeR?= NFTtXpMyODBizszN NXnKcHd5PzJiaB?= NWK1[ZFHcW6mdXPld{BieG:ydH;zbZM> MUSyOFY4PjN7NB?=
SGC-7901 MVfGeY5kfGmxbjDBd5NigQ>? NFrXbIY4PS9zMECvNVI2KM7:TR?= NH\1fG0zPC92OD:3NkBp M{WzdIlv[3KnYYPld{Bk[XOyYYPlMVgh[W6mID25JI1TVkFiZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4UhdWGwbnXy NYLJXXd2OjR4N{[zPVQ>
LMeC  NUTTZ4dvTnWwY4Tpc44hSXO|YYm= NWP0N29wOjBxNUCg{txO MlHlOFghcA>? NF\rdnpl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhS0:[LUKgdJJwfGWrbh?= MWCyOFY2Pjd2Nh?=
CMeC-1 NGjoc5hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{jZfVIxNzVyIN88US=> MVq0PEBp NGW0S5NqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MnrRNlQ3PTZ5NE[=
LMeC NFq2O|JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4DXZlIxNzVyIN88US=> MX[0PEBp NFvsOlBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= Mn3aNlQ3PTZ5NE[=
CMeC-1 M1r0cWZ2dmO2aX;uJGF{e2G7 NIjTelYzOC93MDFOwG0> MojNOFghcA>? M2iyRYlv\HWlZYOgS|EuWyCjcoLld5Q> NVG0fXRlOjR4NU[3OFY>
LMeC MVHGeY5kfGmxbjDBd5NigQ>? NEC0dGwzOC93MDFOwG0> M4jpNVQ5KGh? NITCR4RqdmS3Y3XzJGcyNVNiYYLy[ZN1 M2L0T|I1PjV4N{S2
CMeC-1 MkLFSpVv[3Srb36gRZN{[Xl? MmPsNlAwPTBizszN NHLacJY1QCCq NH3BXpFl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3rMVlI1PjV4N{S2
LMeC MWfGeY5kfGmxbjDBd5NigQ>? M1LqNFIxNzVyIN88US=> MlHGOFghcA>? NUPLR4Jy\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NF\5fYUzPDZ3Nke0Oi=>
CMeC-1 NUTGVXc3TnWwY4Tpc44hSXO|YYm= MVeyNE82OCEQvF2= NF3SRYo1QCCq NUDtV5NucW6mdXPld{Bk[XOyYYPlMVMh[WO2aY\heIlwdg>? NUjkW2ZLOjR4NU[3OFY>
LMeC M2nme2Z2dmO2aX;uJGF{e2G7 NULwfYcxOjBxNUCg{txO MkLUOFghcA>? MVzpcoR2[2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u NH3MXIQzPDZ3Nke0Oi=>
OVCAR-3 M2ixfGNmdGxiVnnhZoltcXS7IFHzd4F6 M1nUVVExKML3TR?= NVnJcm1rOSCq MojQ[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=> NVLx[VZDOjR3MkCyNlc>
OVCAR-3 M4\rOGFxd3C2b4Ppd{BCe3OjeR?= M2HncVExKML3TR?= NHv4UnYyKGh? MofpdJJwdW:2ZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIFxd3C2b4Ppd:Kh MlzJNlQ2OjB{Mke=
OVCAR-3 NEXsNXZHfW6ldHnvckBCe3OjeR?= NUTETZpkOTBiwsXN MYOxJIg> MXjlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmNToEoB?= NUW4WW13OjR3MkCyNlc>
OVCAR-3 NF[xU3RHfW6ldHnvckBCe3OjeR?= MkDyNVAhyrWP NXroZ4tkOSCq NI\HPWxld3ewLYLl[5Vt[XSnczDOSk3PwkJiYXP0bZZifGmxbjDpcoR2[2WmIHL5JJBi[2yrdHH4[Yw> M1W3blI1PTJyMkK3
OVCAR-3 MlXlSpVv[3Srb36gRZN{[Xl? NWPjcGtZOTBiwsXN MXOxJIg> NWjxTYlUcW6qaXLpeJMheGGlbHn0ZZhmdC2rbnT1Z4VlKEGtdDDwbI9{eGixconsZZRqd25? NIPvTYgzPDV{MEKyOy=>
CF33 MoSxSpVv[3Srb36gRZN{[Xl? NXm0SoRqOTByIN88US=> M3zXOFI1KGh? NH36TYNqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbh?= NH3PSIwzPDVyM{e4Ni=>
CF33 NX;6[pdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPIU5kyOC1zMECg{txO M3zrOFAuPCCm NYTlbllCcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFvqcVgzPDVyM{e4Ni=>
CF33 NW\5R3VVTnWwY4Tpc44hSXO|YYm= M37LNVExNTFyMDFOwG0> M16yUFQuOjRiaB?= M4C4NYRm[3KnYYPld{Bk\WyuczDpckB1cGViUzDwbIF{\SCjbnSgbY5kemWjc3XzJINmdGy|IHnuJGcxN0dzIHHydoV{fA>? NWHQNYszOjR3MEO3PFI>
LNCaP NX;OXmhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[yM|UwOTBizszN NU\sU2o1QTZiaB?= MkfTbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?= NGXsTGQzPDJ7Nkm3PC=>
LNCaP M2C2[mFxd3C2b4Ppd{BCe3OjeR?= MYWyM|UwOTBizszN MoLvPVYhcA>? NYfXdGRtcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDheI9zfmG|dHH0bY4> M1i2UlI1Ojl4OUe4
PC-3  MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWiwMVUxKM7:TR?= MoTUOFjjiImq M1jlXolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NF7xO4EzPDF{N{i4Ni=>
PC-3  M{XWd2NmdGxiVnnhZoltcXS7IFHzd4F6 NWTSfpZROC1zMECg{txO NEjtVZA4OiCq M{DmSIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NESz[VYzPDF{N{i4Ni=>

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03590821 Not yet recruiting Healthy University of Pennsylvania November 2019 Early Phase 1
NCT03590821 Not yet recruiting Healthy University of Pennsylvania November 2019 Early Phase 1
NCT03864575 Not yet recruiting Metastatic Cancer Cliniques universitaires Saint-Luc- Université Catholique de Louvain April 15 2019 Phase 2
NCT03864575 Not yet recruiting Metastatic Cancer Cliniques universitaires Saint-Luc- Université Catholique de Louvain April 15 2019 Phase 2
NCT01344200 Not yet recruiting Pharmacokinetics of Celecoxib in Children Children''s Hospital of Eastern Ontario March 2019 Phase 4
NCT03850587 Not yet recruiting Osteoarthritis Knee Yooyoung Pharmaceutical Co. Ltd.|Green Cross Corporation March 3 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products4

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID